Optimizing AAV Manufacturing: Process Intensification with High Salt Lysis and Salt Tolerant Endonuclease

by Amandine Biehler | April 30, 2024

VVT TAP

Essential steps in the manufacturing of adeno-associated virus (AAV) vectors are lysis of cells used to produce the vectors and nuclease treatment. This midstream step relies on detergents to solubilize the lipid bilayer of the cells to release the vectors, followed by digestion of host cell DNA and remaining plasmids using an endonuclease. The digestion step helps to ensure patient safety by reducing any residual DNA to less than 10 ng/dose with a fragment size of less than ~200 base pairs. This digestion step also improves downstream process efficiency.

In a new overview of this process, our experts describe key considerations for both cell lysis and nucleic acid digestion. This overview also describes how the combination of a high salt concentration, and a salt tolerant endonuclease can be used to increase vector titer and infectivity. We used advanced protein engineering techniques to develop the non-animal origin, salt tolerant Benzonase® endonuclease for AAV vector production that can be used at salt concentrations of up to 1000 mM.

We also include a discussion of how the new endonuclease leads to an increase of AAV5 capsid titers by an average of 29% when used in lysis buffer with 500 mM salt. The effect of this salt concentration on AAV2 vector infectivity is also described. When the salt concentration was increased to 500mM, an increase of infectivity of at least 10x was observed, regardless of the detergent used for cell lysis.

Learn more here!

[molongui_author_box]

Related Posts

Starting your journey into manufacturing – choosing a cell line development provider

One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product. …

GEN Regulatory Podcast link LIVE!

The success of cell and gene therapy products in recent years to treat a host of complex diseases…

Assembling a new gene therapy company to develop the next generation of pioneering medicines

Having both recently graduated from our Masters degrees, Christina in Neuroscience from ETH Zürich and Charlotte in Chemistry…

Webinar: Developing A Scalable Upstream Bioreactor Process for Lentiviral Vector Production in Suspension

Gene therapies hold the promise to change lives. As your path to patients accelerates, how can you assure…

Scroll to Top